文献速递心律失常

长QT综合征孕妇心律失常风险与β受体阻滞剂治疗

Arrhythmia risk and β-blocker therapy in pregnant women with long QT syndrome.
PubMed 文献 · Heart · 2017-03-14

研究纳入76例长QT综合征孕妇共136次妊娠,回顾分析β受体阻滞剂治疗组(42次妊娠)与未治疗组(94次妊娠)的临床及电生理特征与妊娠结局。结果显示β受体阻滞剂组仅产后发生2次事件,未治疗组妊娠期及产后共12次事件;β受体阻滞剂组早产和低出生体重儿更常见(OR 4.79,95%CI 1.51至15.21;OR 3.25,95%CI 1.17至9.09)。

要点

  • β受体阻滞剂组仅产后发生2次事件,未治疗组妊娠期6次、产后6次事件。
  • β受体阻滞剂组早产风险升高(OR 4.79,95%CI 1.51至15.21)。
  • β受体阻滞剂组低出生体重儿风险升高(OR 3.25,95%CI 1.17至9.09)。

核心结论

  • 早期诊断和对高危长QT综合征患者使用β受体阻滞剂对预防妊娠期及产后心脏事件重要,且β受体阻滞剂治疗对长QT综合征孕妇的婴儿可能可耐受。

研究设计与样本

  • 回顾性分析76例长QT综合征孕妇共136次妊娠,年龄29±5岁,其中22例LQT1、36例LQT2、1例LQT3、17例基因型未知。
  • 按是否接受β受体阻滞剂治疗分为β受体阻滞剂组(42次妊娠)和未治疗组(94次妊娠)。

主要发现

  • β受体阻滞剂组全部在妊娠前已诊断长QT综合征且有既往事件,而未治疗组65%在妊娠时未诊断。
  • 未治疗组妊娠增加心率,但两组间QT和Tpeak-Tend间期无显著差异。
  • β受体阻滞剂组仅产后发生2次事件,未治疗组妊娠期发生6次、产后发生6次事件。
  • 两组自然流产频率无差异,胎儿生长率和先天性畸形婴儿比例相似。
  • β受体阻滞剂组早产更常见(OR 4.79,95%CI 1.51至15.21),低出生体重儿更常见(OR 3.25,95%CI 1.17至9.09)。

临床怎么用

  • 作者认为早期诊断和对高危长QT综合征患者使用β受体阻滞剂对预防妊娠期及产后心脏事件重要。
  • 作者认为β受体阻滞剂治疗对长QT综合征孕妇的婴儿可能可耐受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy is one of the biggest concerns for women with long QT syndrome (LQTS). OBJECTIVES: This study investigated pregnancy-related arrhythmic risk and the efficacy and safety of β-blocker therapy for lethal ventricular arrhythmias in pregnant women with LQTS (LQT-P) and their babies. METHODS: 136 pregnancies in 76 LQT-P (29±5 years old; 22 LQT1, 36 LQT2, one LQT3, and 17 genotype-unknown) were enrolled. We retrospectively analysed their clinical and electrophysiological characteristics and pregnancy outcomes in the presence (BB group: n=42) or absence of β-blocker therapy (non-BB group: n=94). RESULTS: All of the BB group had been diagnosed with LQTS with previous events, whereas 65% of the non-BB group had not been diagnosed at pregnancy. Pregnancy increased heart rate in the non-BB group; however, no significant difference was observed in QT and Tpeak-Tend intervals between the two groups. In the BB group, only two events occurred at postpartum, whereas 12 events occurred in the non-BB group during pregnancy (n=6) or postpartum period (n=6). The frequency of spontaneous abortion did not differ between the two groups. Fetal growth rate and proportion of infants with congenital malformation were similar between the two groups, but premature delivery and low birthweight infants were more common in those taking BB (OR 4.79, 95% CI 1.51 to 15.21 and OR 3.25, 95% CI 1.17 to 9.09, respectively). CONCLUSIONS: Early diagnosis and β-blocker therapy for high-risk patients with LQTS are important for prevention of cardiac events during pregnancy and the postpartum period, and β-blocker therapy may be tolerated for babies in LQT-P cases.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Ishibashi K, Aiba T, Kamiya C, et al. Arrhythmia risk and β-blocker therapy in pregnant women with long QT syndrome. Heart. 2017. PMID: 28292826. doi:10.1136/heartjnl-2016-310617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。